Emmanuelle Godefroy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4780491/publications.pdf

Version: 2024-02-01

22 papers

851 citations

567281 15 h-index 19 g-index

23 all docs 23 docs citations

23 times ranked 1506 citing authors

#	Article	IF	CITATIONS
1	Human CD4+CD8î±+ Tregs induced by Faecalibacterium prausnitzii protect against intestinal inflammation. JCI Insight, 2022, 7, .	5.0	23
2	Gut Microbiota-Induced Regulatory T Cells in Patients with Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation: Towards Deciphering a Role for These Tregs in aGVHD. Blood, 2020, 136, 34-35.	1.4	0
3	Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. Frontiers in Immunology, 2019, 10, 143.	4.8	72
4	Expression of CCR6 and CXCR6 by Gut-Derived CD4+/CD8α+ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases. Gastroenterology, 2018, 155, 1205-1217.	1.3	42
5	Modulation of human Th17 cell responses through complement receptor 3 (CD11â€⁻b/CD18) ligation on monocyte-derived dendritic cells. Journal of Autoimmunity, 2018, 92, 57-66.	6.5	20
6	Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization. Haematologica, 2016, 101, 1028-1038.	3 . 5	32
7	TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. Haematologica, 2015, 100, 1415-1425.	3.5	73
8	Altered Heme-Mediated Modulation of Dendritic Cell Function in Sickle Cell Alloimmunization. Blood, 2015, 126, 655-655.	1.4	0
9	Activation of Toll-like Receptor-2 by Endogenous Matrix Metalloproteinase-2 Modulates Dendritic-Cell-Mediated Inflammatory Responses. Cell Reports, 2014, 9, 1856-1870.	6.4	33
10	Activation of Toll-like receptor-2 by tumor associated matrix metalloproteinase-2 modulates dendritic cell function. , 2014, 2, .		0
11	Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2. Oncolmmunology, 2012, 1, 109-111.	4.6	7
12	Matrix Metalloproteinase-2 Conditions Human Dendritic Cells to Prime Inflammatory TH2 Cells via an IL-12- and OX40L-Dependent Pathway. Cancer Cell, 2011, 19, 333-346.	16.8	59
13	TLR4 Engagement during TLR3-Induced Proinflammatory Signaling in Dendritic Cells Promotes IL-10–Mediated Suppression of Antitumor Immunity. Cancer Research, 2011, 71, 5467-5476.	0.9	51
14	Folding of Matrix Metalloproteinase-2 Prevents Endogenous Generation of MHC Class-I Restricted Epitope. PLoS ONE, 2010, 5, e11894.	2.5	5
15	KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. Journal of Clinical Investigation, 2008, 118, 3990-4001.	8.2	32
16	Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clinical Immunology, 2007, 122, 163-172.	3.2	16
17	Assessment of CD4+ \hat{A} T cells specific for the tumor antigen SSX-1 in cancer-free individuals. Cancer Immunology, Immunotherapy, 2007, 56, 1183-1192.	4.2	8
18	Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells. Journal of Immunology, 2006, 177, 944-949.	0.8	175

#	Article	lF	CITATION
19	A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. Clinical Immunology, 2006, 118, 188-194.	3.2	10
20	Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clinical Immunology, 2006, 121, 54-62.	3.2	19
21	Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells. Journal of Immunology, 2006, 177, 3100-3107.	0.8	131
22	αvβ3-dependent cross-presentation of matrix metalloproteinase–2 by melanoma cells gives rise to a new tumor antigen. Journal of Experimental Medicine, 2005, 202, 61-72.	8.5	42